Novartis AG (NVS)

85.02
0.11 0.13
NYSE : Health Technology
Prev Close 85.13
Open 84.08
Day Low/High 84.05 / 85.06
52 Wk Low/High 72.30 / 94.19
Volume 1.80M
Avg Volume 1.71M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 217.29B
EPS 3.30
P/E Ratio 25.98
Div & Yield 2.49 (2.92%)

Latest News

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

Biotech Stocks Getting Their Due Respect

Biotech Stocks Getting Their Due Respect

Here are two I think will bounce back before the end of the year.

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.

Three Key Takeaways From Healthcare Earnings Season

Three Key Takeaways From Healthcare Earnings Season

Drug pricing remains front and center as healthcare companies start reporting quarterly results.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

Comcast Is Among 8 Stocks That Are Ready to Change Direction

Comcast Is Among 8 Stocks That Are Ready to Change Direction

These names are showing bullish or bearish reversal patterns over the past week.

Novartis Launches The Galaxies Of Hope App, A Digital Experience For The Neuroendocrine Tumor (NET) Cancer Community

Novartis Launches The Galaxies Of Hope App, A Digital Experience For The Neuroendocrine Tumor (NET) Cancer Community

- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices of patients, caregivers, and physicians in the NET...

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis' device to treat allergic reactions should compete effectively with Mylan's popular EpiPen, according to an analyst.

Stocks Stumble at Friday's Close, Giving Up Most of Day's Gains

Stocks Stumble at Friday's Close, Giving Up Most of Day's Gains

Stocks ended slightly higher Friday, after giving up most of the day's gains in the final minutes of trading.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed the last day of June trading on a high note Friday.

Novartis Doesn't Appear Ready to Make Healthy Move Higher

Novartis Doesn't Appear Ready to Make Healthy Move Higher

The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.

Nike, Deutsche Bank, Goldman Sachs and Novartis - 5 Things You Must Know

Nike, Deutsche Bank, Goldman Sachs and Novartis - 5 Things You Must Know

U.S. stock futures are rising Friday and global stocks rebound on strong gains in China; Deutsche Bank is higher even after receiving a fresh rebuke from the Fed over 'critical deficiencies' in its financial planning; Nike's sales in North America bounce back.

Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning

Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning

Happy Friday! These are the stories you must know ahead of the opening bell.

Novartis Survey Uncovers Real-world Impact Of Immune Thrombocytopenia Or ITP, A Rare Blood Disease, On Patients' Quality Of Life

Novartis Survey Uncovers Real-world Impact Of Immune Thrombocytopenia Or ITP, A Rare Blood Disease, On Patients' Quality Of Life

-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

FDA Publicly Shames Drug Companies to Encourage Generic Competition

FDA Publicly Shames Drug Companies to Encourage Generic Competition

Following up on President Trump's drug pricing speech last week, the FDA posted a list of 39 name-brand drug firms that are allegedly making life tough on generic drug companies.

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Here's what you need to know now for Friday, May 18.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Novartis Now Is Subject to Michael Cohen-Related Probes on 2 Continents

Novartis Now Is Subject to Michael Cohen-Related Probes on 2 Continents

Last week, the Swiss drug giant's $1.2 million in payments to President Trump's fixer Michael Cohen became public. Now the government of Switzerland as well as two U.S. senators are looking into them.

Trade Wars, AT&T's Cohen Drama and Nvidia's Big Beat - 5 Things You Must Know

Trade Wars, AT&T's Cohen Drama and Nvidia's Big Beat - 5 Things You Must Know

U.S. stock futures are slightly higher Friday as Wall Street prepares for the Trump administration's North Korea summit and China trade talks. AT&T and Novartis pick up the pieces. JPMorgan overhauls stock trading.

Novartis Ties to Trump Lawyer Michael Cohen Exposed

Novartis Ties to Trump Lawyer Michael Cohen Exposed

Pharma giant Novartis is now immersed in the muck that is the Trump-Russia probe thanks to $1.2 million in payments to a shell company created by President Trump's fixer Michael Cohen.

Iran Deal, Disney's Earnings and Changes at Facebook - 5 Things You Must Know

Iran Deal, Disney's Earnings and Changes at Facebook - 5 Things You Must Know

U.S. stock futures are higher Wednesday morning as Wall Street digests President Trump's decision to exit the Iran deal. Disney beat on the top and bottom line, while Facebook is making major changes to its executive leadership.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

The drugmakers and health insurer are preparing to unveil first-quarter numbers.

TheStreet Quant Rating: A- (Buy)